A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NCT06465069)
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- City of Hope National Medical Center — Duarte, California
- University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla, California
- UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
- Sarah Cannon Research Institute at HealthOne — Denver, Colorado
- Florida Cancer Specialists and Research Institute — St. Petersburg, Florida
- University of Chicago Hospital — Chicago, Illinois
- IU Simon Cancer Center — Indianapolis, Indiana
- Massachusetts General Hospital — Boston, Massachusetts
- START Midwest Cancer and Hematology Centers of W Michigan — Grand Rapids, Michigan
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) — New York, New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Sarah Cannon Research Institute — Nashville, Tennessee
- Tennessee Oncology PLLC — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
- University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
- START Mountain Region — West Valley City, Utah
- St Vincent's Hospital — Darlinghurst,
- Linear Clinical Research — Nedlands,
- Beijing Cancer hospital — Beijing,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Orlando, Florida
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS — Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) — Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) — Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Anchorage, Alaska
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors — El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.